Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Creeping Toward Compromise: Draft Device User Fee Pact Possible This Month

This article was originally published in The Gray Sheet

Executive Summary

Despite several holdups in user fee negotiations, progress appears to be picking up and FDA hopes to reach a draft agreement with industry by the end of August.

You may also be interested in...

Institute Of Medicine On 510(k) Review Program: Dump It

The Institute of Medicine committee charged with reviewing FDA's 510(k) device pre-market review program is urging the agency to ditch the 35-year-old program and start fresh.

FDA Issues 510(k) Modifications Draft Guidance

FDA is taking another stab at giving device companies advice on how to tell if a change they make to a 510(k)-cleared product warrants a new pre-market submission.

Industry Questions On CDRH Reform Plans Hold Up User Fee Progress

Device industry representatives are demanding that FDA release more details about what resources will be required to support planned regulatory reforms before they will map out a final user fee reauthorization agreement.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts